Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an eye drop for ocular use. It lowers intra‑ocular pressure in patients with open‑angle glaucoma and ocular hypertension. GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers pressure to prevent conversion to glaucoma. - Glaucoma (any type): provides IOP reduction when other therapies are insufficient.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual pigmentation change. - Eye irritation: transient burning or stinging. - Blurred vision: temporary visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: fluid accumulation affecting central vision. - Paradoxical IOP increase: unexpected rise in pressure. - Corneal edema: swelling of the cornea impairing clarity.

Before initiating therapy, consider the following precautions. - Monitor intra‑ocular pressure: regular assessments to ensure therapeutic effect. - Avoid use in active ocular infection: may exacerbate inflammation. - Caution with history of uveitis: increased risk of flare‑ups. - Do not wear contact lenses during treatment: may trap medication. - Assess for hypersensitivity: discontinue if allergic signs appear. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents. Major Interactions (Avoid): - Concomitant prostaglandin analogs: risk of excessive IOP lowering. - Ocular surgery: may delay wound healing. Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive pressure‑lowering effect. - Carbonic anhydrase inhibitor eye drops: potential for over‑reduction of IOP. - Systemic carbonic anhydrase inhibitors: monitor intra‑ocular pressure response.